Gilead Sciences, Inc. $GILD Shares Sold by New York Life Investment Management LLC

New York Life Investment Management LLC decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 181,147 shares of the biopharmaceutical company’s stock after selling 6,424 shares during the period. New York Life Investment Management LLC’s holdings in Gilead Sciences were worth $20,107,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Csenge Advisory Group raised its stake in shares of Gilead Sciences by 319.0% in the 3rd quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock valued at $2,375,000 after purchasing an additional 16,288 shares in the last quarter. Railway Pension Investments Ltd grew its stake in Gilead Sciences by 3.1% in the third quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock worth $157,139,000 after purchasing an additional 42,200 shares in the last quarter. TriaGen Wealth Management LLC bought a new stake in Gilead Sciences in the third quarter valued at about $1,274,000. iA Global Asset Management Inc. raised its stake in Gilead Sciences by 11.6% during the third quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company’s stock valued at $24,630,000 after buying an additional 23,046 shares in the last quarter. Finally, Sector Gamma AS raised its stake in Gilead Sciences by 15.9% during the third quarter. Sector Gamma AS now owns 147,239 shares of the biopharmaceutical company’s stock valued at $16,344,000 after buying an additional 20,239 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

NASDAQ GILD opened at $152.50 on Monday. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $153.13. The firm has a market capitalization of $189.20 billion, a PE ratio of 23.64, a P/E/G ratio of 0.80 and a beta of 0.36. The company’s 50 day simple moving average is $127.38 and its 200 day simple moving average is $121.04. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the transaction, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at $76,504,230. The trade was a 16.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the sale, the director owned 8,920 shares in the company, valued at approximately $1,115,713.60. This trade represents a 35.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 373,037 shares of company stock worth $50,731,512 in the last quarter. Company insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the subject of several research reports. BMO Capital Markets lifted their target price on Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, January 26th. The Goldman Sachs Group raised their price objective on Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a research note on Thursday, January 8th. Mizuho boosted their target price on shares of Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a research note on Friday, November 21st. Leerink Partners increased their target price on shares of Gilead Sciences from $114.00 to $146.00 and gave the stock an “outperform” rating in a report on Friday, January 30th. Finally, Citigroup raised their price target on shares of Gilead Sciences from $140.00 to $156.00 and gave the stock a “buy” rating in a research report on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $136.73.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.